|
1IB1
CRYSTAL STRUCTURE OF THE 14-3-3 ZETA:SEROTONIN N-ACETYLTRANSFERASE COMPLEX
Deposited 2001-03-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
COT COA-S-ACETYL TRYPTAMINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 4000, magnesium chloride, lithium sulfate, DTT, EDTA, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.70 Å
R-free 0.228
|
|
1IB1
CRYSTAL STRUCTURE OF THE 14-3-3 ZETA:SEROTONIN N-ACETYLTRANSFERASE COMPLEX
Deposited 2001-03-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
COT COA-S-ACETYL TRYPTAMINE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;PEG 4000, magnesium chloride, lithium sulfate, DTT, EDTA, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.70 Å
R-free 0.228
|
|
2C1J
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3
Deposited 2005-09-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;0.1 M HEPES PH7.0, 23% ETHYLENE GLYCOL, pH 7.00
|
Resolution 2.60 Å
R-free 0.292
|
|
2C1N
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3
Deposited 2005-09-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;100MM HEPES PH 7.0, 23% ETHYLENE GLYCOL
|
Resolution 2.00 Å
R-free 0.296
|
|
2C1N
Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3
Deposited 2005-09-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;100MM HEPES PH 7.0, 23% ETHYLENE GLYCOL
|
Resolution 2.00 Å
R-free 0.296
|
|
2O02
Phosphorylation independent interactions between 14-3-3 and Exoenzyme S: from structure to pathogenesis
Deposited 2006-11-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
BEZ BENZOIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;285 K;pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 285K
|
Resolution 1.50 Å
R-free 0.212
|
|
2WH0
Recognition of an intrachain tandem 14-3-3 binding site within protein kinase C epsilon
Deposited 2009-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.4;16 MG/ML PROTEIN 9% (W/V) POLYETHYLENE GLYCOL 3350, 25 MM CALCIUM ACETATE, 25 MM SODIUM FLUORIDE, pH 7.4
|
Resolution 2.25 Å
R-free 0.235
|
|
2WH0
Recognition of an intrachain tandem 14-3-3 binding site within protein kinase C epsilon
Deposited 2009-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.4;16 MG/ML PROTEIN 9% (W/V) POLYETHYLENE GLYCOL 3350, 25 MM CALCIUM ACETATE, 25 MM SODIUM FLUORIDE, pH 7.4
|
Resolution 2.25 Å
R-free 0.235
|
|
3CU8
Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome
Deposited 2008-04-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
MG MAGNESIUM ION × 2
PPI PROPANOIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;0.1M (Sodium propionate, sodium cacodylate, BIS-TRIS propane), 27% PEG 1500, 2mM DTT, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.259
|
|
3NKX
Impaired binding of 14-3-3 to Raf1 is linked to Noonan and LEOPARD syndrome
Deposited 2010-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
PPI PROPANOIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;0.1M (Sodium propionate, sodium cacodylate, BIS-TRIS propane), 27% PEG 1500, 2mM DTT, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.247
|
|
3RDH
X-ray induced covalent inhibition of 14-3-3
Deposited 2011-04-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
3RD 4-[(E)-{4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]pyridin-2-yl}diazenyl]benzoic acid × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;289 K;25% PEG3350, 100 mM Tris-HCl pH 8.5, 10 mM MgCl2, 1 mM NiCl2, 1% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.39 Å
R-free 0.286
|
|
3RDH
X-ray induced covalent inhibition of 14-3-3
Deposited 2011-04-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain B
1–245(245 aa)
Chain C
1–245(245 aa)
|
Not recorded
|
3RD 4-[(E)-{4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]pyridin-2-yl}diazenyl]benzoic acid × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;289 K;25% PEG3350, 100 mM Tris-HCl pH 8.5, 10 mM MgCl2, 1 mM NiCl2, 1% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.39 Å
R-free 0.286
|
|
3RDH
X-ray induced covalent inhibition of 14-3-3
Deposited 2011-04-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
3RD 4-[(E)-{4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]pyridin-2-yl}diazenyl]benzoic acid × 4
NI NICKEL (II) ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;289 K;25% PEG3350, 100 mM Tris-HCl pH 8.5, 10 mM MgCl2, 1 mM NiCl2, 1% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.39 Å
R-free 0.286
|
|
4BG6
14-3-3 interaction with Rnd3 prenyl-phosphorylation motif
Deposited 2013-03-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 3
FAR FARNESYL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;0.17 M SODIUM ACETATE; 0.085 M TRIS, PH 8.5; 25.5% (W/V) PEG4000, 15% (V/V) GLYCEROL
|
Resolution 2.30 Å
R-free 0.273
|
|
4FJ3
14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide
Deposited 2012-06-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–230(230 aa)
Fragment:UNP residues 1-230
Chain B
1–230(230 aa)
Fragment:UNP residues 1-230
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;0.1 M Na-acetate pH 7.0, 0.8 M NaH2PO4 and 1.2 M K2HPO4 , VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.95 Å
R-free 0.208
|
|
4HKC
14-3-3-zeta in complex with S1011 phosphorylated integrin alpha-4 peptide
Deposited 2012-10-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
|
Not recorded
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;0.1M Na HEPES (pH 7.5), 25% PEG 2000 MME, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.239
|
|
4IHL
Human 14-3-3 isoform zeta in complex with a diphoyphorylated C-RAF peptide and Cotylenin A
Deposited 2012-12-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–230(230 aa)
Fragment:UNP residues 1-230
Chain B
1–230(230 aa)
Fragment:UNP residues 1-230
|
Not recorded
|
K POTASSIUM ION × 2
1F5 (1R,3aS,4R,5R,6R,9aR,10E)-6-({(1S,2R,4S,5R,6R,8S,9S)-5-hydroxy-2-(methoxymethyl)-9-methyl-9-[(2S)-oxiran-2-yl]-3,7,10,1 1-tetraoxatricyclo[6.2.1.0~1,6~]undec-4-yl}oxy)-1-(methoxymethyl)-4,9a-dimethyl-7-(propan-2-yl)-1,2,3,3a,4,5,6,8,9,9a-de cahydrodicyclopenta[a,d][8]annulene-1,5-diol × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;0.1 M NA-ACETATE PH 7.0, 0.8 M NAH2PO4 AND 1.2 M K2HPO4, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.243
|
|
4N7G
Crystal structure of 14-3-3zeta in complex with a peptide derived from ExoS
Deposited 2013-10-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Fragment:UNP residues 1-230
|
Not recorded
|
P6G HEXAETHYLENE GLYCOL × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;277.15 K;0.2 M sodium chloride, 0.1 M sodium acetate, pH 4.5, 40% v/v PEG300, VAPOR DIFFUSION, temperature 277.15K
|
Resolution 2.25 Å
R-free 0.223
|
|
4N7Y
Crystal structure of 14-3-3zeta in complex with a 8-carbon-linker cyclic peptide derived from ExoS
Deposited 2013-10-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Fragment:UNP residues 1-230
Chain B
1–230(230 aa)
Fragment:UNP residues 1-230
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;277.15 K;0.09 M HEPES sodium, pH 7.5, 1.26 M sodium citrate, 10% v/v glycerol, VAPOR DIFFUSION, temperature 277.15K
|
Resolution 2.16 Å
R-free 0.256
|
|
4N84
Crystal structure of 14-3-3zeta in complex with a 12-carbon-linker cyclic peptide derived from ExoS
Deposited 2013-10-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Fragment:UNP residues 1-230
Chain B
1–230(230 aa)
Fragment:UNP residues 1-230
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 8;277.15 K;1 M potassium sodium tartrate, 0.1 M sodium chloride, 0.1 M imidazole, pH 8.0, cryoprotectant: 20% glycerol, VAPOR DIFFUSION, temperature 277.15K
|
Resolution 2.50 Å
R-free 0.249
|
|
4WRQ
Crystal Structure of 14-3-3 zeta with Chibby peptide
Deposited 2014-10-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;16-20% PEG 3350, ammonium formate
|
Resolution 2.41 Å
R-free 0.256
|
|
4ZDR
Crystal structure of 14-3-3[zeta]-LKB1 fusion protein
Deposited 2015-04-18
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–230(230 aa)
Fragment:UNP residues 1-230,UNP residues 333-340
Chain B
1–230(230 aa)
Fragment:UNP residues 1-230,UNP residues 333-340
|
Mutation:T240E
Mutation:T240E
|
GOL GLYCEROL × 3
SO4 SULFATE ION × 2
TME PROPANE × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;289 K;1.4 M Li2SO4, 0.1 M BIS-TRIS propane
|
Resolution 2.90 Å
R-free 0.245
|
|
5D2D
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768
Deposited 2015-08-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
CL CHLORIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;277 K;HEPES, NaCl, DTT, Li2SO4, Glycine, K2HPO4
|
Resolution 2.10 Å
R-free 0.220
|
|
5D3F
Crystal structure of human 14-3-3 zeta in complex with CFTR R-domain peptide pS753-pS768 and stabilizer fusicoccin-A
Deposited 2015-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
FSC FUSICOCCIN × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;277 K;HEPES, NaCl, DTT, PEG6000
|
Resolution 2.74 Å
R-free 0.303
|
|
5EWZ
Small-molecule stabilization of the 14-3-3/Gab2 PPI interface
Deposited 2015-11-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
BEZ BENZOIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277.15 K;1.2 M sodium hydrogen phosphate, 0.8 M dipotassium hydrogen phosphate,
0.2 M lithium sulfate, 0.1 M CAPS
|
Resolution 2.34 Å
R-free 0.244
|
|
5EXA
Small-molecule stabilization of the 14-3-3/Gab2 PPI interface
Deposited 2015-11-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
5SO Fusicoccin A-THF derivative × 2
BEZ BENZOIC ACID × 2
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277.15 K;0.17 M ammonium acetate, 0.085 M sodium citrate pH 5.6, 25.5% (w/v) PEG 4000, 15% (v/v) glycerol.
|
Resolution 1.95 Å
R-free 0.234
|
|
5J31
Crystal structure of 14-3-3zeta in complex with an alkyne cross-linked cyclic peptide derived from ExoS
Deposited 2016-03-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
BEZ BENZOIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;1.26 M Tri-Sodium Citrate, 0.09 M HEPES pH 7.5, 10% Glycerol
|
Resolution 2.40 Å
R-free 0.219
|
|
5JM4
Crystal structure of 14-3-3zeta in complex with a cyclic peptide involving an adamantyl and a dicarboxy side chain
Deposited 2016-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
2–229(228 aa)
Chain B
2–229(228 aa)
|
Not recorded
|
BEZ BENZOIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;0.09 M HEPES sodium salt pH 7.5; 1.26 M tri-Sodium citrate; 10 %(v/v) Glycerol
|
Resolution 2.34 Å
R-free 0.244
|
|
5M35
The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
Deposited 2016-10-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
2–230(229 aa)
Chain B
2–230(229 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 2
BEZ BENZOIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.6;277.15 K;0.17 M Ammonium acetate; 0.085 M Sodium citrate pH 5.6; 25.5%(w/v) PEG 4000; 15%(v/v) Glycerol
|
Resolution 2.38 Å
R-free 0.277
|
|
5M36
The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
Deposited 2016-10-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
2–230(229 aa)
Chain B
2–230(229 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
9SZ (1R,5S,9S,16R,20R,24S,28S,35R)-3,22-Bis(dihydroxyphosphoryloxy)tridecacyclo[22.14.1.15,20.19,16.128,35.02,23.04,21.06,19.08,17.010,15.025,38.027,36.029,34]dotetraconta-2(23),3,6,8(17),10,12,14,18,21,25,27(36),29,31,33,37-pentadecaene × 4
BEZ BENZOIC ACID × 2
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.6;277.15 K;0.17 M Ammonium acetate; 0.085 M Sodium citrate pH 5.6; 25.5% (w/v) PEG 4000; 15% (v/v) Glycerol
|
Resolution 2.45 Å
R-free 0.274
|
|
5M37
The molecular tweezer CLR01 stabilizes a disordered protein-protein interface
Deposited 2016-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
9SZ (1R,5S,9S,16R,20R,24S,28S,35R)-3,22-Bis(dihydroxyphosphoryloxy)tridecacyclo[22.14.1.15,20.19,16.128,35.02,23.04,21.06,19.08,17.010,15.025,38.027,36.029,34]dotetraconta-2(23),3,6,8(17),10,12,14,18,21,25,27(36),29,31,33,37-pentadecaene × 4
BEZ BENZOIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;0.17 M Ammonium acetate;0.085 M tri-Sodium citrate pH 5.6; 25.5 %(w/v) PEG 4000; 15 %(v/v) Glycerol
|
Resolution 2.35 Å
R-free 0.275
|
|
5NAS
Crystal structure of human 14-3-3 zeta in complex with PI4KIIIB peptide
Deposited 2017-02-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;291 K;MES, PEG, ethylene glycol
|
Resolution 2.08 Å
R-free 0.231
|
|
5ULO
Crystal Structure of 14-3-3 zeta in Complex with a Serine 124-phosphorylated TBC1D7 peptide
Deposited 2017-01-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 2
UNX UNKNOWN LIGAND × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;25% PEG 3350, 0.2 M NaCl, 0.1 M HEPES pH7.5,5%~15% Ethylene Glycol
|
Resolution 2.14 Å
R-free 0.270
|
|
5WXN
Structure of the LKB1 and 14-3-3 complex
Deposited 2017-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;289 K;0.15 M ammonium chloride, 18% PEG3350
|
Resolution 2.93 Å
R-free 0.254
|
|
5XY9
Structure of the MST4 and 14-3-3 complex
Deposited 2017-07-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
GOL GLYCEROL × 1
PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8.5;289 K;0.2M MgCl2, 0.1M Tris pH 8.5, 25% PEG 3350
|
Resolution 2.30 Å
R-free 0.245
|
|
6EF5
14-3-3 with peptide
Deposited 2018-08-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;277.15 K;0.1 M Tris pH 8.5, 0.1 M MgCl2, 0.001 M NiCl2 and 22% PEG 3350
|
Resolution 2.44 Å
R-free 0.244
|
|
6EF5
14-3-3 with peptide
Deposited 2018-08-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;277.15 K;0.1 M Tris pH 8.5, 0.1 M MgCl2, 0.001 M NiCl2 and 22% PEG 3350
|
Resolution 2.44 Å
R-free 0.244
|
|
6EJL
Structure of 14-3-3 zeta in complex with ASK1 14-3-3 binding motif
Deposited 2017-09-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;291 K;Morpheus HT-96, condition H12
|
Resolution 2.38 Å
R-free 0.215
|
|
6EWW
Structure of 14-3-3 zeta in complex with CaMKK2 14-3-3 binding motif
Deposited 2017-11-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;291.15 K;PEG 2000, TRIS-HCl, HEPES, magnesium chloride, sodium fluoride, TCEP
|
Resolution 2.68 Å
R-free 0.234
|
|
6EWW
Structure of 14-3-3 zeta in complex with CaMKK2 14-3-3 binding motif
Deposited 2017-11-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–230(230 aa)
Chain D
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;291.15 K;PEG 2000, TRIS-HCl, HEPES, magnesium chloride, sodium fluoride, TCEP
|
Resolution 2.68 Å
R-free 0.234
|
|
6F08
14-3-3 zeta in complex with the human Son of sevenless homolog 1 (SOS1)
Deposited 2017-11-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298.15 K;0.1 M phosphate citrate pH 4.2, 36% (v/v) PEG 300
|
Resolution 1.90 Å
R-free 0.267
|
|
6F08
14-3-3 zeta in complex with the human Son of sevenless homolog 1 (SOS1)
Deposited 2017-11-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain I
1–230(230 aa)
Chain J
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298.15 K;0.1 M phosphate citrate pH 4.2, 36% (v/v) PEG 300
|
Resolution 1.90 Å
R-free 0.267
|
|
6F09
Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide
Deposited 2017-11-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain P
1–230(230 aa)
Chain S
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298.15 K;0.1 M phosphate citrate pH 4.4; 40% PEG 300
|
Resolution 1.59 Å
R-free 0.225
|
|
6F09
Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide
Deposited 2017-11-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain Q
1–230(230 aa)
Chain R
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298.15 K;0.1 M phosphate citrate pH 4.4; 40% PEG 300
|
Resolution 1.59 Å
R-free 0.225
|
|
6F09
Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide
Deposited 2017-11-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain P
1–230(230 aa)
Chain S
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298.15 K;0.1 M phosphate citrate pH 4.4; 40% PEG 300
|
Resolution 1.59 Å
R-free 0.225
|
|
6F09
Binary complex of 14-3-3 zeta with ubiquitin specific protease 8 (USP8) pSer718 peptide
Deposited 2017-11-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain Q
1–230(230 aa)
Chain R
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298.15 K;0.1 M phosphate citrate pH 4.4; 40% PEG 300
|
Resolution 1.59 Å
R-free 0.225
|
|
6FN9
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
Deposited 2018-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
DW8 [2-[2-oxidanylidene-2-[[3-[2-[2-[2-[3-oxidanylidene-3-(propylamino)propoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]amino]ethoxy]phenyl]phosphonic acid × 2
BEZ BENZOIC ACID × 2
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;0.09 M HEPES sodium salt pH 7.5
1.26 M tri-Sodium citrate
10 %(v/v) Glycerol
|
Resolution 2.27 Å
R-free 0.256
|
|
6FNA
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
Deposited 2018-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
DWE [2-[2-oxidanylidene-2-[[3-[2-[2-[2-[3-oxidanylidene-3-[2-[3-[2-[2-[2-[[4-[2-(2-phosphonophenoxy)ethanoylamino]phenyl]carbonylamino]ethoxy]ethoxy]ethoxy]propanoylamino]ethylamino]propoxy]ethoxy]ethoxy]ethylcarbamoyl]phenyl]amino]ethoxy]phenyl]phosphonic acid × 2
BEZ BENZOIC ACID × 2
CA CALCIUM ION × 2
CL CHLORIDE ION × 4
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;0.18 M Magnesium chloride
0.09 M Sodium HEPES pH 7.5
10% (v/v) Glycerol
27% (v/v) Isopropanol
|
Resolution 2.12 Å
R-free 0.236
|
|
6FNB
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
Deposited 2018-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
BEZ BENZOIC ACID × 2
GOL GLYCEROL × 3
CA CALCIUM ION × 2
CL CHLORIDE ION × 4
DWQ [2-[2-oxidanylidene-2-[[3-[2-[5-[3-oxidanylidene-3-[3-[2-[2-[3-[3-[2-[2-[2-[[3-[2-(2-phosphonophenoxy)ethanoylamino]phenyl]carbonylamino]ethoxy]ethoxy]ethoxy]propanoylamino]propoxy]ethoxy]ethoxy]propylamino]propoxy]pentoxy]ethylcarbamoyl]phenyl]amino]ethoxy]phenyl]phosphonic acid × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;0.09 M HEPES sodium salt pH 7.5
1.26 M tri-Sodium citrate
10 %(v/v) Glycerol
|
Resolution 2.30 Å
R-free 0.248
|
|
6FNC
Mono- and bivalent 14-3-3 inhibitors for characterizing supramolecular lysine-PEG interactions in proteins
Deposited 2018-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
DWK [2-[2-oxidanylidene-2-[[3-[3-[2-[2-[3-[[4-[2-(2-phosphonophenoxy)ethanoylamino]phenyl]carbonylamino]propoxy]ethoxy]ethoxy]propylcarbamoyl]phenyl]amino]ethoxy]phenyl]phosphonic acid × 2
BEZ BENZOIC ACID × 2
GOL GLYCEROL × 2
CA CALCIUM ION × 2
CL CHLORIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277.15 K;0.18 M Magnesium chloride,
0.09 M Sodium HEPES pH 7.5
10%(v/v) Glycerol
27%(v/v) Isopropanol
|
Resolution 2.12 Å
R-free 0.246
|
|
6Q0K
Structure of a MAPK pathway complex
Deposited 2019-08-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain X
1–245(245 aa)
Chain Y
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 6.80 Å
|
|
6RLZ
Crystal Structure of 14-3-3zeta in complex with a macrocyclic 8-mer peptide derived from ExoS
Deposited 2019-05-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;0.2 M Magnesium formate
20% PEG 3350
pH 7.5
|
Resolution 3.70 Å
R-free 0.292
|
|
6U2H
BRAF dimer bound to 14-3-3
Deposited 2019-08-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
29L 2-{4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridin-4-yl)-1H-pyrazol-1-yl}ethanol × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;PEG 6000
Tris pH 7.5
|
Resolution 2.50 Å
R-free 0.263
|
|
6XAG
Apo BRAF dimer bound to 14-3-3
Deposited 2020-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;289 K;100 mM HEPES pH 7.5, 200 mM ammonium sulfate, 23% (w/v) PEG 3350
|
Resolution 3.30 Å
R-free 0.300
|
|
6YMO
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pS617 peptide
Deposited 2020-04-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
SAL 2-HYDROXYBENZOIC ACID × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 6.8;277.15 K;2.04 M ammonium sulfate, 0.2 M sodium citrate supplemented with 10% of an additive buffer containing 0.33% w/v 3-aminobenzoic acid, 0.33% w/v 3-aminosalicylic acid, 0.33% w/v salicylic acid and 0.02 M HEPES sodium pH 6.8
|
Resolution 2.02 Å
R-free 0.234
|
|
6YO8
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 peptide
Deposited 2020-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 8.3;277.15 K;1.29 M MgCl2, 22.5% PEG 3350, 0.1 M Tris pH 8.3, supplemented with 10% of an additive buffer containing 40% v/v of 2,5-Hexanediol
|
Resolution 2.09 Å
R-free 0.238
|
|
6YO8
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 peptide
Deposited 2020-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–230(230 aa)
Chain D
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 8.3;277.15 K;1.29 M MgCl2, 22.5% PEG 3350, 0.1 M Tris pH 8.3, supplemented with 10% of an additive buffer containing 40% v/v of 2,5-Hexanediol
|
Resolution 2.09 Å
R-free 0.238
|
|
6YOS
Binary complex of 14-3-3 zeta with Glucocorticoid Receptor (GR) pT524 pS617 peptide
Deposited 2020-04-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 6.8;293.15 K;0.35 M MgCl2, 24.4% PEG 3350, 0. 1 M Bis Tris pH 5.5 supplemented with 10% of an additive buffer containing 0.06 M CHAPS, 0.06 M HEPES, 0.06 M Tris, 0.25% w/v Hexamminecobalt(III) chloride and 0.02 M HEPES sodium pH 6.8.
|
Resolution 2.75 Å
R-free 0.261
|
|
6ZFD
14-3-3 zeta bound to the phosphorylated 18E6 C-terminus
Deposited 2020-06-17
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–229(229 aa)
Chain B
1–229(229 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;277 K;19% PEG4000, 0.1M cacodylate, 20%glycerol as a cryoprotectant
|
Resolution 1.90 Å
R-free 0.207
|
|
7D8H
CRTC1 pSer64 peptide in complex with 14-3-3 zeta
Deposited 2020-10-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;200mM Ammonium acetate, 100mM Bis-Tris (pH6.5), 25% (w/v) Polyethylene glycol 3350
|
Resolution 2.42 Å
R-free 0.246
|
|
7D8P
CRTC1 pSer151 peptide in complex with 14-3-3 zeta
Deposited 2020-10-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;200mM Ammonium acetate, 100mM Bis-Tris (pH6.5), 25% (w/v) Polyethylene glycol 3350
|
Resolution 2.00 Å
R-free 0.229
|
|
7D9V
CRTC1 pSer245 peptide in complex with 14-3-3 zeta
Deposited 2020-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;200mM Ammonium acetate, 100mM Bis-Tris (pH6.5), 25% (w/v) Polyethylene glycol 3350
|
Resolution 2.21 Å
R-free 0.240
|
|
7MFD
Autoinhibited BRAF:(14-3-3)2:MEK complex with the BRAF RBD resolved
Deposited 2021-04-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
ZN ZINC ION × 2
CHU N-(3-fluoro-4-{[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2H-chromen-3-yl]methyl}pyridin-2-yl)-N'-methylsulfuric diamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.66 Å
|
|
7MFE
Autoinhibited BRAF:(14-3-3)2 complex with the BRAF RBD resolved
Deposited 2021-04-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
1–245(245 aa)
Chain C
1–245(245 aa)
|
Not recorded
|
ZN ZINC ION × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.07 Å
|
|
7MFF
Dimeric (BRAF)2:(14-3-3)2 complex bound to SB590885 Inhibitor
Deposited 2021-04-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
215 (1Z)-5-(2-{4-[2-(DIMETHYLAMINO)ETHOXY]PHENYL}-5-PYRIDIN-4-YL-1H-IMIDAZOL-4-YL)INDAN-1-ONE OXIME × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.89 Å
|
|
7Q16
Human 14-3-3 zeta fused to the BAD peptide including phosphoserine-74
Deposited 2021-10-18
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–229(229 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;0.16 M calcium acetate, 0.08 M sodium cacodylate pH 6.5, 14.4 % w/v PEG 8000, 20 % v/v glycerol
|
Resolution 2.36 Å
R-free 0.241
|
|
7ZIT
14-3-3 in complex with SARS-COV2 N phospho-peptide
Deposited 2022-04-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
ACT ACETATE ION × 2
GOL GLYCEROL × 1
BEZ BENZOIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293.15 K;9 0.2 M Sodium acetate
0.1 M Sodium cacodylate pH 6.5
30% (w/v) PEG 8000
|
Resolution 1.79 Å
R-free 0.205
|
|
8A9G
Binary complex of 14-3-3 zeta Glucocorticoid Receptor (GR) pT524 peptide stabilised by (R)-para chloropyrrolidone1
Deposited 2022-06-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
BTB 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 2
QJK 5-[(2~{R})-3-(4-chlorophenyl)carbonyl-2-(4-nitrophenyl)-4-oxidanyl-5-oxidanylidene-2~{H}-pyrrol-1-yl]-2-oxidanyl-benzoic acid × 2
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;277.15 K;0.4 M MgCl2
27% w/v PEG 3350
0.1 M Bis Tris 6.5 pH
|
Resolution 1.96 Å
R-free 0.261
|
|
8AH2
Crystal structure of human 14-3-3 zeta fused to the NPM1 peptide including phosphoserine-48
Deposited 2022-07-20
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–229(229 aa)
|
Mutation:S58A,E75A,K76A,K77A,K157A,K158A,E159A
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;288 K;0.01 M CoCl2, 0.1 M MES, pH 6.5, 2.2 M (NH4)2SO4
|
Resolution 2.90 Å
R-free 0.323
|
|
8AH2
Crystal structure of human 14-3-3 zeta fused to the NPM1 peptide including phosphoserine-48
Deposited 2022-07-20
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain C
1–229(229 aa)
|
Mutation:S58A,E75A,K76A,K77A,K157A,K158A,E159A
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;288 K;0.01 M CoCl2, 0.1 M MES, pH 6.5, 2.2 M (NH4)2SO4
|
Resolution 2.90 Å
R-free 0.323
|
|
8QDV
Structure of 14-3-3 zeta delta C with the bivalent tau-pS214-pS324 peptide
Deposited 2023-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–230(230 aa)
Chain B
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2M Sodium Fluoride, 0.1M bis-tris propane pH 6.5, 20% w/v PEG 3350
|
Resolution 2.50 Å
R-free 0.260
|
|
8QDV
Structure of 14-3-3 zeta delta C with the bivalent tau-pS214-pS324 peptide
Deposited 2023-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain E
1–230(230 aa)
Chain G
1–230(230 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;277 K;0.2M Sodium Fluoride, 0.1M bis-tris propane pH 6.5, 20% w/v PEG 3350
|
Resolution 2.50 Å
R-free 0.260
|
|
8VYO
Cryo-EM Structure of the BRAF WT monomer
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
2–230(229 aa)
Chain C
2–230(229 aa)
|
Not recorded
|
ZN ZINC ION × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 3.74 Å
|
|
8VYP
Cryo-EM Structure of the BRAF V600E monomer
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
AGS PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 3.29 Å
|
|
8VYQ
Cryo-EM Structure of the BRAF V600K monomer
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 4.43 Å
|
|
8VYR
Cryo-EM Structure of the BRAF V600E monomer bound to GDC0879
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
1–245(245 aa)
Chain C
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 4.32 Å
|
|
8VYS
Cryo-EM Structure of the BRAF V600E monomer bound to PLX8394
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
2–245(244 aa)
Chain C
2–245(244 aa)
|
Not recorded
|
A1AEN (3S)-N-{3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}-3-fluoropyrrolidine-1-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 3.06 Å
|
|
8VYU
Cryo-EM Structure of the BRAF WT monomer bound to PLX8394
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
1–245(245 aa)
Chain C
1–245(245 aa)
|
Not recorded
|
A1AEN (3S)-N-{3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}-3-fluoropyrrolidine-1-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 4.07 Å
|
|
8VYV
Cryo-EM Structure of the BRAF K601E monomer
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 5.86 Å
|
|
8VYW
Cryo-EM Structure of the BRAF D594G monomer
Deposited 2024-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE;Chameleon system (SPT Labtech)
|
Resolution 4.76 Å
|
|
8WE2
14-3-3 zeta complexed with S609 phosphorylated peptide derived from GPIb alpha cytoplasmic domain
Deposited 2023-09-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;0.2M Sodium Acetate, 20% PEG 3350
|
Resolution 2.11 Å
R-free 0.238
|
|
8WF6
14-3-3 zeta complexed with S559 phosphorylated peptide derived from GPIb alpha cytoplasmic domain
Deposited 2023-09-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;2% Tacsimate pH7.0, 0.1M Hepes pH7.5, 20% PEG 3350
|
Resolution 2.47 Å
R-free 0.238
|
|
8WF6
14-3-3 zeta complexed with S559 phosphorylated peptide derived from GPIb alpha cytoplasmic domain
Deposited 2023-09-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
SIN SUCCINIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;291 K;2% Tacsimate pH7.0, 0.1M Hepes pH7.5, 20% PEG 3350
|
Resolution 2.47 Å
R-free 0.238
|
|
9FUM
Dimeric 14-3-3 zeta in complex with MAP2c peptide containing pS435
Deposited 2024-06-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
CD CADMIUM ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;100 mM HEPES pH(7.5), 400 mM Sodium acetate, 8mM Cadmium sulfate
|
Resolution 2.45 Å
R-free 0.275
|
|
9FVL
Dimeric 14-3-3 zeta in complex with unphosphorylated MAP2c peptide
Deposited 2024-06-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
1–245(245 aa)
Chain B
1–245(245 aa)
|
Not recorded
|
CD CADMIUM ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293.15 K;100 mM HEPES pH(7.5), 400 mM Sodium acetate, 8mM Cadmium sulfate
|
Resolution 2.08 Å
R-free 0.283
|
|
9O2Z
Autoinhibited BRAF:(14-3-3)2:MEK complex from Insect cells
Deposited 2025-04-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain C
1–245(245 aa)
Chain D
1–245(245 aa)
|
Not recorded
|
ZN ZINC ION × 2
CHU N-(3-fluoro-4-{[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2H-chromen-3-yl]methyl}pyridin-2-yl)-N'-methylsulfuric diamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.83 Å
|
|
9SV3
Local refinement of EloB/EloC/VHL/CV2a/14-3-3zeta/ERa from pose 1
Deposited 2025-09-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 7
PDB declaration: heptameric
|
Chain D
1–245(245 aa)
Chain I
1–245(245 aa)
|
Not recorded
|
A1JQT ~{N}'-[(2~{S})-3,3-dimethyl-1-[(2~{S},4~{R})-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]-4-oxidanyl-pyrrolidin-1-yl]-1-oxidanylidene-butan-2-yl]-~{N}-[(2~{S})-2-[(1~{E},3~{R},4~{S},8~{R},9~{R},10~{R},11~{S},14~{S})-14-(methoxymethyl)-3,10-dimethyl-8-[(2~{S},3~{R},4~{S},5~{S},6~{R})-6-(2-methylbut-3-en-2-yloxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-4,9-bis(oxidanyl)-6-tricyclo[9.3.0.0^{3,7}]tetradeca-1,6-dienyl]propyl]tridecanediamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.30 Å
|
|
9UJ2
14-3-3 zeta chimera with the S202R peptide of SARS-CoV-2 N (residues 200-213)
Deposited 2025-04-16
|
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–229(229 aa)
Chain B
1–229(229 aa)
|
Mutation:S202R,S58A,E73A,K74A,K75A,K157A,K158A,E159A
Non-standard monomer:Yes (specific site not provided by mmCIF)
Mutation:S202R,S58A,E73A,K74A,K75A,K157A,K158A,E159A
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
EDO 1,2-ETHANEDIOL × 16
PEG DI(HYDROXYETHYL)ETHER × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;288 K;1.8M Ammonium sulfate, 0.1M BIS-TRIS pH 6.5, 2% v/v Polyethylene glycol monomethyl ether 550
|
Resolution 1.80 Å
R-free 0.233
|